Table 4 Retention of HIVIS-03 trial volunteers
Volunteers who were: | Total | Males | Females | p-value* |
|---|---|---|---|---|
n (%) | n (%) | n (%) | ||
Randomized | 79 | 57 | 22 | |
Exited after Randomization | 19 (24.1%) | 12 (21.1%) | 7 (31.8%) | 0.32 |
Enrolled | 60 | 45 | 15 | |
Vaccination Visits | ||||
Received 1st DNA/Placebo | 60 (100%) | 45 (100%) | 15 (100%) | - |
Received 2nd DNA/Placebo | 60 (100%) | 45 (100%) | 15 (100%) | - |
Received 3rd DNA/Placebo | 59 (98.3%) | 44 (97.8%) | 15 (100%) | 0.99 |
Received 1st MVA/Placebo | 50 (83.3%) | 41 (91.1%) | 9 (60%) | 0.02 |
Received 2nd MVA/Placebo | 42 (70%) | 37 (82.2%) | 5 (33.3%) | 0.002 |
Safety and Immunogenicity visits | ||||
2 weeks post 2nd DNA/Placebo | 60 (100%) | 45 (100%) | 15 (100%) | - |
2 weeks post 3rd DNA/Placebo | 59 (98.3%) | 44 (97.8%) | 15 (100%) | 0.99 |
2 weeks post 1st MVA/Placebo | 50 (83.3%) | 41 (91.1%) | 9 (60%) | 0.02 |
8 weeks post 1st MVA/Placebo | 50 (83.3%) | 41 (91.1%) | 9 (60%) | 0.02 |
24 weeks post 1st MVA/Placebo | 42 (70%) | 37 (82.2%) | 5 (33.3%) | 0.002 |
2 weeks post 2nd MVA/Placebo | 42 (70%) | 37 (82.2%) | 5 (33.3%) | 0.002 |
4 weeks post 2nd MVA/Placebo | 42 (70%) | 37 (82.2%) | 5 (33.3%) | 0.002 |
24 weeks post 2nd MVA/Placebo | 40 (66.7%) | 35 (77.8%) | 5 (33.3%) | 0.002 |